Australia markets closed

Evoke Pharma, Inc. (EV00.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
2.6800+0.0600 (+2.29%)
As of 03:56PM CEST. Market open.
Full screen
Previous close2.6200
Open2.7200
Bid2.7000 x N/A
Ask2.7400 x N/A
Day's range2.6800 - 2.7200
52-week range1.9144 - 15.0000
Volume2
Avg. volume226
Market cap9.375M
Beta (5Y monthly)0.54
PE ratio (TTM)N/A
EPS (TTM)-2.8370
Earnings date08 Nov 2022 - 14 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Evoke Pharma and EVERSANA Expand Patient Access to GIMOTI® With New Telehealth Solution

    Patients With Symptoms of Diabetic Gastroparesis Now Have Direct-to-Patient Treatment Support Powered by UpScriptHealthSOLANA BEACH, Calif. and CHICAGO, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company primarily focused on treatments for gastrointestinal (GI) diseases, and EVERSANA™, an independent provider of global commercial services to the life science industry, today announced that Evoke, through its wide-scale commercialization partner

  • GlobeNewswire

    Evoke Pharma Reports Second Quarter 2022 Financial Results

    Total new inbound prescriptions over 500 for first time, 24% increase over Q1; New cumulative prescribers up 23%; Net revenue increased by 11%SOLANA BEACH, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the second quarter ended June 30, 2022, and recent corporate developments. “Evoke delivered a solid second quarter based o

  • GlobeNewswire

    Evoke Pharma to Report Second Quarter Results on August 10, 2022

    SOLANA BEACH, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the Company is scheduled to release its second quarter on Wednesday, August 10, 2022, after the market closes. Management will host a conference call on Wednesday, August 10, 2022, at 4:30 p.m. ET to discuss the results. The dial-in numbers for the conference call are (800) 343-4849 and (203) 5